source
- Pharma deals in China face heightened IP risk under U.S. BIOSECURE ActPharma companies are increasing licensing activity in China, but experts say patent attorneys must now factor in the geopolitical implications of the BIOSECURE Act. The legislation seeks to compil…
- Oak Hill Bio to merge with RA Capital SPAC as InnoCare’s TYK2 candidate reports positive Phase 3 resultsOak Hill Bio, a biotech focused on Angelman syndrome, announced it will combine with RA Capital’s special purpose acquisition company, Research Alliance Corporation III. The transaction will give O…